Literature DB >> 2117529

Possible roles for frequent salivary antiepileptic drug monitoring in the management of epilepsy.

G K Herkes1, M J Eadie.   

Abstract

Salivary levels of phenytoin, phenobarbitone, carbamazepine and carbamazepine-epoxide correlate with the simultaneous plasma water levels of these substances, after correcting for the effects of pH differences between saliva and plasma in the case of phenobarbitone. Saliva is easy and painless to collect, and salivary levels of the drugs are conveniently measured. Frequent (often daily) monitoring of pre-dose morning anticonvulsant drug concentrations in saliva over periods of weeks or months in 3 groups of epileptic subjects showed that (i) in some but not all poorly controlled epileptic patients seizures tended to occur on days when salivary anticonvulsant levels were lower than on non-seizure days, (ii) in such subjects it was possible to estimate an anticipated optimal drug concentration and dose to minimize seizure activity from the plot of seizure frequency against drug concentrations, (iii) in women with 'catamenial' epilepsy, salivary anticonvulsant levels were lower on perimenstrual days than at mid-cycle in half of the subjects studied, and (iv) in pregnant epileptic women the time course of the change in drug levels relative to dose could be followed more closely throughout pregnancy and the post-natal period than was practicable when using blood level measurements. Frequent measurement of salivary anticonvulsant concentrations appears a promising and inexpensive adjunct to the investigation and management of certain problem areas in epilepsy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117529     DOI: 10.1016/0920-1211(90)90090-i

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  7 in total

Review 1.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 2.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

3.  Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes.

Authors:  Annie R Peng; Robert Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; Caryn Lerman; Rachel F Tyndale
Journal:  Drug Alcohol Depend       Date:  2018-06-26       Impact factor: 4.492

Review 4.  Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs.

Authors:  A D Kashuba; A N Nafziger
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

5.  Measures and predictors of varenicline adherence in the treatment of nicotine dependence.

Authors:  Annie R Peng; Mark Morales; E Paul Wileyto; Larry W Hawk; Paul Cinciripini; Tony P George; Neal L Benowitz; Nicole L Nollen; Caryn Lerman; Rachel F Tyndale; Robert Schnoll
Journal:  Addict Behav       Date:  2017-07-12       Impact factor: 3.913

Review 6.  Enabling robust quantitative readout in an equipment-free model of device development.

Authors:  Elain Fu
Journal:  Analyst       Date:  2014-10-07       Impact factor: 4.616

Review 7.  Pregnancy and the Control of Epileptic Seizures: A Review.

Authors:  Mervyn J Eadie
Journal:  Neurol Ther       Date:  2021-05-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.